Vanda Pharmaceuticals Inc.
NASDAQ:VNDABiotechnology
-$0.20 today
- Market cap
- $226.76M
- Beta
- 0.60
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$4.03
Volume 0.95M
Average 1.29M
VNDA Investing Cash Flow
Net cash used in or generated by investments in assets, acquisitions, and securities.
Vanda Pharmaceuticals Inc.NASDAQ: VNDA
Investing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Investing cash flow dips below year-ago levels
Q1 FY2026 investing cash flow of $20.23M fell 53.9% year over year, behind the +59.3% change in trailing-twelve-month investing cash flow. Sequentially, it fell 54.9% from the prior quarter. Over 3 fiscal years it compounded at +23.9% a year.
Context
- Investing cash flow amounted to 43.9% of revenue in FY2025, up 35.1 pp from a year earlier.
- Investing cash flow increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -53.9% toward the trailing-twelve-month pace of +59.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Investing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 94.86M USD
- Year-over-year change
- +644.2%
| Period | Period end | Investing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 94.86M | +644.2% |
| FY2024 | 2024-12-31 | (17.43M) | -44.6% |
| FY2023 | 2023-12-31 | (12.06M) | -124.1% |
| FY2022 | 2022-12-31 | 49.93M | +165.1% |
| FY2021 | 2021-12-31 | (76.7M) | — |
Investing Cash Flow vs competitors
How VNDA compares with its peers on the latest reported figures
- VNDA's LTM Mar 2026 investing cash flow of $71.19M is the 6th largest of the 11 companies compared; the peer median is $10.2M.
- Its year-over-year change of +59.3% is the 5th highest of 11, against a peer median of +28.3%.
- Investing cash flow amounts to 32.7% of revenue for VNDA, versus a peer median of 147.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $151.8M | -3115.8% | — | — | |
| LTM Mar 2026 | $139.01M | +382.8% | — | 2422.7% | |
| LTM Mar 2026 | $132.92M | +56.5% | — | — | |
| LTM Mar 2026 | $92.35M | +117.8% | — | 253.0% | |
| LTM Mar 2026 | $81.05M | -2.1% | — | — | |
| LTM Mar 2026 | $71.19M | +59.3% | +23.9% | 32.7% | |
| LTM Mar 2026 | $59.8M | +0.1% | -3.4% | — | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $11.36M | +118.5% | — | — |
| LTM Mar 2026 | $9.03M | +188.3% | — | — | |
| LTM Mar 2026 | $831K | -41.0% | — | 41.2% | |
| LTM Mar 2026 | $59.66K | -89.1% | -69.0% | 0.1% | |
| Peer median (excluding VNDA) | $10.2M | +28.3% | -36.2% | 147.1% | |
Competitors are the stored peer set for VNDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 33.15M | 6.28M | 2.51M | (18.9M) | (220.47M) |
| Depreciation & Amortization | 2.84M | 2.73M | 3.01M | 8.13M | (950K) |
| Deferred Income Tax | 6.75M | 1.13M | (1.29M) | (6.48M) | 81.44M |
| Stock-Based Compensation | 15.37M | 16.28M | 14.04M | 12.43M | 9.47M |
| Change in Working Capital | 2.74M | 6.07M | (747K) | (6.56M) | 8.31M |
| Accounts Receivables | (2.47M) | (1.09M) | (707K) | (13.01M) | (7.46M) |
| Inventory | (2.23M) | (4.48M) | (771K) | (29K) | (3.47M) |
| Accounts Payables | 3.04M | 11.79M | (10.98M) | 1.71M | 15.82M |
| Other Working Capital | 4.4M | (151K) | 11.72M | 4.78M | 3.42M |
| Other Non-Cash Items | 3.37M | (507K) | (4.73M) | (4.38M) | 12.76M |
| Operating Cash Flow | 64.21M | 31.98M | 12.8M | (15.76M) | (109.44M) |
| Capital Expenditures | (552K) | (679K) | (383K) | (490K) | (998K) |
| Acquisitions (Net) | 0 | 0 | (100.67M) | (4.23M) | 0 |
| Purchases of Investments | (420.46M) | (349.26M) | (512.61M) | (364.77M) | (112.38M) |
| Sales of Investments | 344.32M | 399.86M | 601.6M | 352.06M | 208.24M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (76.7M) | 49.93M | (12.06M) | (17.43M) | 94.86M |
| Debt Repayment | 0 | 0 | 0 | (155K) | (1.99M) |
| Common Stock Issued | 3.55M | 734K | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | (915K) |
| Financing Cash Flow | 3.55M | 734K | 0 | (155K) | (2.91M) |
| Effect of Forex Changes | (85K) | 315K | 47K | (163K) | 126K |
| Net Change in Cash | (9.02M) | 82.96M | 792K | (33.51M) | (17.36M) |
| Free Cash Flow | 63.66M | 31.31M | 12.42M | (16.25M) | (110.44M) |
Vanda Pharmaceuticals Inc.
NASDAQ:VNDA
Intrinsic Alpha fair value
Locked
Current Price
$3.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.